학술논문

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Document Type
Article
Source
In Blood Advances 8 August 2023 7(15):4089-4101
Subject
Lymphoid Neoplasia
Immunobiology and Immunotherapy
Language
ISSN
2473-9529